TEVA:NYE-Teva Pharmaceutical Industries Limited American Depositary Shares (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 16.88

Change

+0.29 (+1.75)%

Market Cap

USD 38.25B

Volume

0.01B

Analyst Target

USD 12.19
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Its products include Copaxone, Azilect and Provigil.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 80.66B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 42.46B
HLN Haleon plc

N/A

USD 39.18B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 11.67B
CTLT Catalent Inc

N/A

USD 10.02B
ELAN Elanco Animal Health

N/A

USD 9.03B
PRGO Perrigo Company PLC

N/A

USD 3.85B
PBH Prestige Brand Holdings Inc

N/A

USD 3.33B
EVT Eaton Vance Tax Advantaged Div..

N/A

USD 3.26B
BHC Bausch Health Companies Inc

N/A

USD 2.32B

ETFs Containing TEVA

EIS iShares MSCI Israel ETF 9.81 % 0.59 %

N/A

USD 0.14B
FLWR:SW 5.80 % 0.00 %

N/A

N/A
VIDI Vident International Equi.. 0.66 % 0.63 %

N/A

USD 0.38B
IWFS:LSE iShares MSCI World Size F.. 0.19 % 0.00 %

N/A

USD 0.23B
ALFI 0.00 % 0.88 %

N/A

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
GWL 0.00 % 0.34 %

N/A

N/A
ISRPF iShares Public Limited Co.. 0.00 % 0.00 %

N/A

USD 2.22B
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
ISRCF iShares V Public Limited .. 0.00 % 0.00 %

N/A

N/A
ISRHF iShares V Public Limited .. 0.00 % 0.00 %

N/A

N/A
ISRUF iShares V Public Limited .. 0.00 % 0.00 %

N/A

N/A
ISRZF iShares II Public Limited.. 0.00 % 0.00 %

N/A

N/A
ISRIF iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
ISRVF iShares Public Limited Co.. 0.00 % 0.00 %

N/A

N/A
ISRWF iShares II Public Limited.. 0.00 % 0.00 %

N/A

N/A
ISRNF iShares V Public Limited .. 0.00 % 0.00 %

N/A

N/A
ISRRF iShares Public Limited Co.. 0.00 % 0.00 %

N/A

USD 1.81B
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 61.69% 94% A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.69% 94% A 98% N/A
Trailing 12 Months  
Capital Gain 122.99% 94% A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 122.99% 94% A 98% N/A
Trailing 5 Years  
Capital Gain 55.29% 77% C+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.29% 77% C+ 65% D
Average Annual (5 Year Horizon)  
Capital Gain 5.61% 63% D 59% D-
Dividend Return 5.61% 56% F 51% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.18% 63% D 45% F
Risk Adjusted Return 22.29% 63% D 44% F
Market Capitalization 38.25B 81% B- 88% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.40 73% 35%
Price/Book Ratio 1.99 50% 43%
Price / Cash Flow Ratio 11.55 47% 33%
Price/Free Cash Flow Ratio 20.84 19% 13%
Management Effectiveness  
Return on Equity -7.36% 56% 19%
Return on Invested Capital 1.76% 47% 30%
Return on Assets 4.54% 75% 69%
Debt to Equity Ratio 241.95% 18% 13%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector